Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$43 Mln
Revenue (TTM)
$58 Mln
Net Profit (TTM)
$0 Mln
ROE
-2.3 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.9
Industry P/E
--
EV/EBITDA
-36.8
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
23,949,200
CFO
$-436.16 Mln
EBITDA
$-305.20 Mln
Net Profit
$-469.69 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Celularity Inc. Class A (CELU)
| -15.9 | 4.8 | 11.5 | -47.6 | -66.4 | -55.5 | -- |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|
|
Celularity Inc. Class A (CELU)
| -15.7 | -80.9 | -74.8 | -53.5 | 10.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Celularity Inc. Class A (CELU)
|
1.8 | 43.1 | 57.7 | -46.6 | -85.3 | -357.1 | -- | 4.9 |
| 50.5 | 8,079.8 | 1,208.8 | 131.7 | 13.4 | 6.3 | 62.1 | 3.9 | |
| 128.0 | 8,274.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 149.5 | 7,460.2 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 53.5 | 10,095.9 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 41.6 | 11,341.9 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19 | 5.3 | |
| 298.3 | 8,688.9 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.4 | 14.6 | |
| 26.7 | 10,732.1 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.1 | |
| 124.4 | 12,371.7 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.2 | 4.9 | |
| 283.4 | 12,470.6 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 12.9 | 2.2 |
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent... stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey. Address: 170 Park Avenue, Florham Park, NJ, United States, 07932 Read more
Founder, CEO & Chairman
Dr. Robert Joseph Hariri M.D., Ph.D.
Founder, CEO & Chairman
Dr. Robert Joseph Hariri M.D., Ph.D.
Headquarters
Florham Park, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Celularity Inc Class A (CELU) stood at $ 153 Mln as on 31-Mar-25
The share price of Celularity Inc Class A (CELU) is $1.75 (NASDAQ) as of 13-Jun-2025 16:00 EDT. Celularity Inc Class A (CELU) has given a return of -66.42% in the last 3 years.
Celularity Inc Class A (CELU) has a market capitalisation of $ 43 Mln as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Celularity Inc Class A (CELU) is 4.88 times as on 12-Jun-2025, a 86% premium to its peers’ median range of 2.63 times.
Since, TTM earnings of Celularity Inc Class A (CELU) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Celularity Inc Class A (CELU) and enter the required number of quantities and click on buy to purchase the shares of Celularity Inc Class A (CELU).
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey. Address: 170 Park Avenue, Florham Park, NJ, United States, 07932
The CEO & director of Dr. Robert Joseph Hariri M.D., Ph.D.. is Celularity Inc Class A (CELU), and CFO & Sr. VP is Dr. Robert Joseph Hariri M.D., Ph.D..
There is no promoter pledging in Celularity Inc Class A (CELU).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| Celularity Inc. Class A (CELU) | Ratios |
|---|---|
|
Return on equity(%)
|
-357.05
|
|
Operating margin(%)
|
-85.31
|
|
Net Margin(%)
|
-80.85
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Celularity Inc Class A (CELU) was $0 Mln.
$-0.01
(
